Business
Pharmaceutical Industry Under Scrutiny
A House lawmaker is investigating potential retaliation by the three largest pharmacy benefit managers (PBMs) against independent pharmacies. Meanwhile, GSK sees progress in its oncology division with upcoming drug approvals.
Coverage timeline — 2 articles
STAT News
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
2026-10-26 16:20 UTC
STAT News
A House lawmaker is investigating whether the three largest PMS targeted independent pharmacies withretaliatory audits.
2026-10-26 16:26 UTC